ねころんで読めるウィズコロナ時代の感染対策

出版社： メディカ出版
著者：
発行日： 2022-02-01
分野： 臨床医学：内科  >  感染症/AIDS
ISBN： 9784840478472
電子書籍版： 2022-02-01 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

商品紹介

「正しい感染対策が知りたい、でも、難しいのは苦手。時間もない」…そんなあなたのために、感染対策の専門家が“誰でもわかる”新しい感染対策のルールを解説。新型コロナウイルス対応に2年間奔走し、「デマやうわさではない、正しい感染対策を知ってほしい」と強く願う矢野邦夫先生が、感染を正しく怖がり、ウィズコロナ時代に必要な感染対策を伝授する一冊！

目次

  • 【1章】なるほど編
    ◆店頭からアルコールが消える
    手指消毒の重要性が理解された
    ◆世界の日本化
    咳エチケットからユニバーサル・マスキングへ
    ◆鼻出しマスク禁止
    二重マスクの勧め
    ◆ユニバーサル・マスキングの功罪
    病原体から逃れる副作用
    ◆羊質虎皮
    個人防護具は適切に着脱すべきである
    ◆受験勉強のノウハウ
    手指の高頻度接触面をターゲットとした消毒や洗浄
    ◆おもちゃの指輪が10万円
    環境の消毒や洗浄
    ◆似て非なるもの
    空気感染とエアロゾル感染
    ◆ゴルフは外見だけでは上達しない！
    外見だけの感染対策から真の感染対策へ
    ◆油断大敵
    休憩室、更衣室、食堂での感染対策
    ◆デマとガセ
    新型コロナウイルスについての啓発が重要である
    ◆距離を空けると疎遠になる
    社会的距離から身体的距離へ

    【2章】落とし穴編
    ◆シャンプーとボディソープ
    次亜塩素酸水とアルコールの手指消毒薬
    ◆砂浜に置かれた濡れた手
    手指乾燥機の使用禁止
    ◆人は飛行機に乗って空を飛ぶ
    ウイルスは飛沫や飛沫核に乗って空を飛ぶ
    ◆ことわざの誤解
    不潔な手袋のままで商品や周囲環境に触れない
    ◆まったく別のことを関連させない！
    換気がよくても、飛沫感染する
    ◆「石に灸（きゅう）」「尻が来る」
    病院玄関での発熱チェック
    ◆野生動物の足跡と糞
    PCR検査が陽性の意味
    ◆今日の情けは明日の仇
    PCR検査が陰性の意味

    【3章】知っておきたいこと編
    ◆「不言実行」「有言実行」
    無症状感染者の感染性
    ◆変わり者
    変異株
    ◆自動車教習所
    ワクチンの「効力（efficacy）」と「有効性（effectiveness）」
    ◆スイスチーズ
    ワクチンの感染予防、発症予防、重症化予防
    ◆防御を突破する
    突き抜け感染、ブレイクスルー感染
    ◆小事に拘わりて大事を忘るな
    mRNAワクチンが人間の遺伝子に入り込む？
    ◆天秤にかける
    ワクチンによる心筋炎かウイルスによる心筋炎のどちらを選ぶ？
    ◆大相撲の土俵
    ゾーニング
    ◆生有る者は死有り
    環境での病原体の生存時間
    ◆新鮮な空気
    換気と空気清浄機
    ◆出世魚
    院内感染対策→医療関連感染対策→感染対策

    【4章】今後の展望編
    ◆ブースター
    新型コロナワクチンの3回目接種
    ◆一難去ってまた一難
    ほかのウイルスの流行
    ◆ワクチンを接種しない権利
    それは権利の主張か乱用か？
    ◆出口戦略とシナリオ
    適切な感染対策の縮小
    ◆ウィズコロナのシナリオ(1)
    ワクチンへの期待
    ◆ウィズコロナのシナリオ(2)
    抗コロナウイルス薬への期待
    ◆ウィズコロナのシナリオ(3)
    変異株への期待
    ◆抗コロナウイルス薬（経口薬）の作用機序
    目的のためなら手段を選ばず

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 なるほど編

P.15 掲載の参考文献
1) Oran DP, et al. Prevalence of asymptomatic SARS-CoV-2 infection. Ann Intern Med. 2021 ; 174 (2) : 286-7.
PubMed
2) Moghadas SM, et al. The implications of silent transmission for the control of COVID-19 outbreaks. Proc Natl Acad Sci U S A. 2020 ; 117 (30) : 17513-5.
PubMed
3) Lavezzo E, et al. ; Imperial College COVID-19 Response Team. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. Nature. 2020 ; 584 (7821) : 425-9.
 
4) Varia M, et al. Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. CMAJ. 2003 ; 169 (4) : 285-92.
 
5) Chen YC, et al. SARS in hospital emergency room. Emerg Infect Dis. 2004 ; 10 (5) : 782-8.
PubMed
6) CDC. Respiratory hygiene/Cough etiquette in healthcare settings. http://www.cdc.gov/flu/professionals/infectioncontrol/resphygiene.htm
 
7) World Health Organization Writing Group. Nonpharmaceutical Interventions for Pandemic Influenza, International Measures. Emerg Infect Dis. 2006 ; 12 (1) : 81-7.
PubMed
8) Cheng PKC, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet. 2004 ; 363 (9422) : 1699-700.
PubMed
9) Moghadas SM, et al. The implications of silent transmission for the control of COVID-19 outbreaks. Proc Natl Acad Sci U S A. 2020 ; 117 (30) : 17513-5.
PubMed
P.19 掲載の参考文献
1) Brook JT, et al. Maximizing fit for cloth and medical procedure masks to improve performance and reduce SARS-CoV-2 transmission and exposure, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7007e1.htm
 
P.22 掲載の参考文献
1) 厚生労働省. 水痘. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkakukansenshou/varicella/index.html
 
2) 東京都感染症情報センター. 流行性耳下腺炎 Mumps. 2015年9月11日. http://idsc.tokyo-eiken.go.jp/diseases/mumps/
 
P.24 掲載の参考文献
1) Garner JS. Guidelines for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. https://wonder.cdc.gov/wonder/prevguid/p0000419/p0000419.asp
 
P.26 掲載の参考文献
1) CDC. Guidelines for environmental infection control in health-care facilities, 2013. https://www.cdc.gov/infectioncontrol/pdf/guidelines/environmental-guidelines-P.pdf
 
2) CDC. Science brief : SARS-CoV-2 and surface (fomite) transmission for indoor community environments. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/surfacetransmission.html
 
P.29 掲載の参考文献
1) Rutala WA, et al. Guideline for disinfection and sterilization in healthcare facilities, 2008. https://www.cdc.gov/infectioncontrol/pdf/guidelines/disinfection-guidelines-H.pdf
 
2) CDC. Guidelines for environmental infection control in health-care facilities, 2003. https://www.cdc.gov/infectioncontrol/pdf/guidelines/environmental-guidelines-P.pdf
 
3) 厚生労働省. 新型コロナウイルスの消毒・除菌方法について (厚生労働省・経済産業省・消費者庁特設ページ). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/syoudoku_00001.html
 
4) CDC. Science brief : SARS-CoV-2 and surface (fomite) transmission for indoor community environments. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/surfacetransmission.html
 
P.33 掲載の参考文献
1) CDC. Guideline for isolation precautions : Preventing transmission of infectious agents in healthcare settings, 2007. https://www.cdc.gov/infectioncontrol/pdf/guidelines/isolation-guidelines-H.pdf
PubMed
2) CDC. Aerosols. https://www.cdc.gov/niosh/topics/aerosols/
 
3) WHO. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. 2020. https://www.who.int/publications/i/item/10665-331495
 
P.36 掲載の参考文献
1) CDC. Guidance for wearing masks. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-coverguidance.html
 
2) CDC. Guideline for hand hygiene in health-care settings, 2002. https://www.cdc.gov/mmwr/PDF/rr/rr5116.pdf
 
P.38 掲載の参考文献
1) CDC. Guidance for wearing masks. 2021. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-coverguidance.html
 
P.40 掲載の参考文献
1) WHO. Coronavirus disease (COVID-19) advice for the public : Mythbusters. 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters
 
P.43 掲載の参考文献
1) Unicef. Physical not social distancing. 2020. https://www.unicef.org/sudan/press-releases/physical-not-social-distancing
 
2) CDC. Guideline for isolation precautions : Preventing transmission of infectious agents in healthcare settings, 2007. https://www.cdc.gov/infectioncontrol/pdf/guidelines/isolation-guidelines-H.pdf
PubMed
3) WHO. COVID-19 : physical distancing. https://www.who.int/westernpacific/emergencies/covid-19/information/physical-distancing
 
4) CDC. COVID-19 : How to protect yourself & others. 2021. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html
 
5) 厚生労働省. 新型コロナウイルスを想定した「新しい生活様式」の実践例を公表しました. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_newlifestyle.html
 
6) CDC. Guidance for COVID-19 prevention in K-12 schools. 2021. https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-guidance.html
 

2章 落とし穴編

P.48 掲載の参考文献
1) 厚生労働省. 次亜塩素酸水と次亜塩素酸ナトリウムの同類性に関する資料. https://www.mhlw.go.jp/shingi/2009/08/dl/s0819-8k.pdf
 
2) 経済産業省ほか. 「次亜塩素酸水」の使い方・販売方法等について (製造・販売事業者の皆さまへ). 令和2年6月26日. https://www.meti.go.jp/press/2020/06/20200626013/20200626013-5.pdf
 
P.51 掲載の参考文献
1) Marples RR, et al. A laboratory model for the investigation of contact transfer of microorgamism. J Hyg (Lond). 1979 ; 82 (2) : 237-48.
PubMed
2) WHO. Coronavirus disease (COVID-19) advice for the public : Mythbusters. 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters
 
P.54 掲載の参考文献
1) 内閣官房. 新型コロナウイルス感染症対策. https://corona.go.jp/proposal/
 
2) CDC. Guidance for wearing masks. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-coverguidance.html
 
P.58 掲載の参考文献
1) Szablewski CM, et al. SARS-CoV-2 Transmission and infection among attendees of an overnight camp-Georgia, June 2020. https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6931e1-H.pdf
 
P.61 掲載の参考文献
1) Oran DP, et al. Prevalence of asymptomatic SARS-CoV-2 infection. Ann Intern Med. 2021 ; 174 (2) : 286-7.
PubMed
2) Dzien C, et al. Covid-19 screening : are forehead temperature measurements during cold outdoor temperatures really helpful?. Wien Klin Wochenschr. 2021 ; 133 (7-8) : 331-5.
 
3) Stave GM, et al. Worksite temperature screening for COVID-19. J Occup Environ Med. 2021 ; 63 (8) : 638-41.
PubMed
4) Pana BC, et al. Real-world evidence : The low validity of temperature screening for COVID-19 triage. Front. Public Health. 2021. https://doi.org/10.3389/fpubh.2021.672698
 
P.64 掲載の参考文献
1) Wolfel R, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 ; 581 (7809) : 465-9.
PubMed

3章 知っておきたいこと編

P.72 掲載の参考文献
1) Oran DP, et al. Prevalence of asymptomatic SARS-CoV-2 infection : A narrative review. Ann Intern Med. 2020 ; 173 (5) : 362-7.
PubMed
2) Moghadas SM, et al. The implications of silent transmission for the control of COVID-19 outbreaks. Proc Natl Acad Sci USA. 2020 ; 117 (30) : 17513-5.
PubMed
3) Lavezzo E, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. Nature. 2020 ; 584 (7821) : 425-9.
PubMed
P.76 掲載の参考文献
1) WHO. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
 
P.79 掲載の参考文献
1) CDC. Science brief : COVID-19 vaccines and vaccination. 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinatedpeople.html
 
P.83 掲載の参考文献
1) Thompson MG, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers-eight U.S. locations, December 2020-March 2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7013e3-H.pdf
 
2) Pilishvili T, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel-33 U. S. sites, January- March 2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7020e2-H.pdf
 
3) Tenforde MW, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 among hospitalized adults aged > 65 Years-United States, January-March 2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7018e1-H.pdf
 
4) Moline HL, et al. Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged > 65 years-COVID-NET, 13 states, February-April 2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7032e3-H.pdf
 
5) CDC. Science brief : COVID-19 vaccines and vaccination. 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinatedpeople.html
 
P.88 掲載の参考文献
1) CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC-United States, January 1-April 30, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7021e3-H.pdf
 
2) Brosh-Nissimov T, et al. BNT162b2 vaccine breakthrough : clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021. https://doi.org/10.1016/j.cmi.2021.06.036
 
3) Tenforde MW, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. medRxiv. 2021. https://doi.org/10.1101/2021.07.08.21259776
 
4) Christensen PA, et al. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. medRxiv. 2021. https://doi.org/10.1101/2021.07.19.21260808
 
5) Muller L, et al. SARS-CoV-2 infection in fully vaccinated individuals of old age strongly boosters the humoral immune response. medRxiv. 2021. https://doi.org/10.1101/2021.07.19.21260563
 
6) Jones NK, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. Elife. 2021 ; 10 : e68808.
PubMed
7) Levine-Tiefenbrun M, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021 ; 27 (5) : 790-2.
PubMed
8) McEllistrem MC, et al. Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab263
 
9) Petter E, et al. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. medRxiv. 2021. https://doi.org/10.1101/2021.02.08.21251329
 
10) Marks M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain : a cohort study. Lancet Infect Dis. 2021. https://doi.org/10.1101/2020.10.27.20220277
 
11) Brown CM, et al. Outbreak of SARS-CoV-2 infections, iIncluding COVID-19 vaccine breakthrough infections, associated with large public gatherings-Barnstable County, Massachusetts, July 2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7031e2-H.pdf
 
12) CDC. Delta variant : What we know about the science. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html
 
13) Chia PY, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccinebreakthrough infections : a multi-center cohort study. 2021. https://doi.org/10.1101/2021.07.28.21261295
 
P.95 掲載の参考文献
1) CDC. Overview of myocarditis and pericarditis. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/02-COVIDOster-508.pdf
 
2) Gargano JW, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients : Update from the Advisory Committee on Immunization PracticesUnited States, June 2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7027e2-H.pdf
 
3) Daniels CJ, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection results from the big ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021. https://jamanetwork.com/journals/jamacardiology/fullarticle/2780548
 
4) Boehmer TK, et al. Association between COVID-19 and myocarditis using hospital-based administrative data-United States, March 2020-January 2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7035e5-H.pdf
 
P.98 掲載の参考文献
1) 国立国際医療研究センターほか. 急性期病院における 新型コロナウイルス感染症アウトブレイクでのゾーニングの考え方. 2020年. http://dcc.ncgm.go.jp/information/pdf/covid19_zoning_clue.pdf
 
P.100 掲載の参考文献
1) Van Doremalen N, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 ; 382 (16) : 1564-7.
PubMed
P.102 掲載の参考文献
1) Lindsley WG, et al. Efficacy of portable air cleaners and masking for reducing indoor exposure to simulated exhaled SARS-CoV-2 aerosols-United States, 2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7027e1-H.pdf
 
P.104 掲載の参考文献
1) CDC. Guideline for isolation precaution : Preventing transmission of infectious agents in healthcare settings, 2007. https://www.cdc.gov/infectioncontrol/pdf/guidelines/isolation-guidelines-H.pdf
PubMed

4章 今後の展望編

P.109 掲載の参考文献
1) CDC. Epidemiology and prevention of vaccine-preventable diseases. https://www.cdc.gov/vaccines/pubs/pinkbook/index.html
 
2) Bar-On YM, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Me. 385 (15),2021, 1393-400. https://www.nejm.org/doi/full/10.1056/NEJMoa2114255
 
P.111 掲載の参考文献
1) Olsen SJ, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic-United States, 2020-2021. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7029a1-H.pdf
 
P.115 掲載の参考文献
1) CDC. Science brief : COVID-19 vaccines and vaccination. 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinatedpeople.html
 
P.120 掲載の参考文献
1) Heimdal I, et al. Human Coronavirus in Hospitalized Children With Respiratory Tract Infections : A 9-Year Population-Based Study From Norway. J Infect Dis. 2019 ; 219 (8) : 1198-206.
PubMed
2) Reed SE. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers : evidence of heterogeneity among 229E-related strains.J Med Virol. 1984 ; 13 (2) : 179-92.
PubMed
3) Christie A, et al. Guidance for implementing COVID-19 prevention strategies in the context of varying community transmission levels and vaccination coverage. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7030e2-H.pdf
 
P.125 掲載の参考文献
1) 国立感染症研究所. 2008/09 インフルエンザシーズンにおけるインフルエンザ (A/H1N1) オセルタミビル耐性株 (H275Y) の国内発生状況 [第2報]. 2009. http://idsc.nih.go.jp/iasr/30/350/pr3503.html
 

書評

最近チェックした商品履歴

Loading...